CharlesErlichmanMD

Oncology • Rochester, MN

Gastrointestinal Cancer, Hematologic Oncology

Professor, Oncology, Mayo Medical School

Join to view full profile

Dr. Erlichman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Erlichman's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511
Is this information wrong?

Summary

Dr. Charles Erlichman is an oncologist in Rochester, MN. He received his medical degree from University of Toronto Faculty of Medicine and has been in practice 43 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in clinical research, combined modality therapy, gastrointestinal oncology, peritoneal neoplasms, and cell survival.

Education & Training

University of Toronto Faculty of MedicineClass of 1974, MD

Certifications & Licensure

MN State Medical License 1994 - 2019

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 1995

Clinical Trials

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Start of enrollment: 1999 Apr 01
Completed
Phase 1
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 1999 Aug 01
Completed
Phase 1
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Jan 01
Completed
Phase 1
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Aug 01
Completed
Phase 1
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Start of enrollment: 2004 Feb 01
Completed
Phase 2
Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2004 Nov 01
Terminated
Phase 1
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Oct 01
Completed
Phase 1
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies Start of enrollment: 2004 Sep 01
Completed
Phase 1
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 2008 Aug 01
Completed
Phase 1
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Start of enrollment: 2009 Mar 31
Active, not recruiting
Phase 1
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer Start of enrollment: 2007 Nov 01
Terminated
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Start of enrollment: 2009 Sep 08
Completed
Phase 2
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Start of enrollment: 2012 Mar 05
Completed
Phase 1
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors Start of enrollment: 2015 Feb 18
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid, Carrie Strand, Jack Fiskum, Michael Menefee, Grace Lin, L. Austin Doyle, Percy Ivy, Charles Erlichma...> ;Investigational New Drugs. 2021 Sep 13
19 citations
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
Zhaohui Jin, Jesse G. Dixon, Jack Fiskum, Hiral D. Parekh, Frank A. Sinicrope, Greg Yothers, Carmen J. Allegra, Norman Wolmark, Daniel G. Haller, Hans-Joachim Schmoll,...> ;Journal of the National Cancer Institute. 2021 Aug 18
67 citations
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Tri...
Romain Cohen, Julien Taieb, Jack Fiskum, Greg Yothers, Richard M. Goldberg, Takayuki Yoshino, Steven R. Alberts, Carmen J. Allegra, Aimery de Gramont, Jean Francois Se...> ;Journal of Clinical Oncology. 2021 Feb 20
15 citations
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Keith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples, Boon Cher Goh, Nina J. Karlin, Madeleine A. Kane, Douglas Adkins, Julian R....> ;Thyroid. 2020 Sep 8
14 citations
Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Ryan M. Carr, Narjust Duma, Angela L. McCleary-Wheeler, Luciana L. Almada, David L. Marks, Rondell P. Graham, Thomas C. Smyrk, Val J. Lowe, Mitesh J. Borad, George P. ...> ;Pancreatology. 2020 Jul 14
17 citations
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
Angela L. McCleary-Wheeler, Ryan M. Carr, Shanique R. Palmer, Thomas C. Smyrk, Jacob B. Allred, Luciana L. Almada, Ezequiel J. Tolosa, Maria J. Lamberti, David L. Mark...> ;Pancreatology. 2020 Jan 1
14 citations
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
Hao Xie, Jun Yin, Manisha H. Shah, Michael E. Menefee, Keith C. Bible, Diane Reidy-Lagunes, Madeleine A. Kane, David I. Quinn, David R. Gandara, Charles Erlichman, Ale...> ;Investigational New Drugs. 2019 Jan 1
4 citations
A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups.
Jun Yin, Rui Qin, Daniel J. Sargent, Charles Erlichman, Qian Shi> ;Journal of Biopharmaceutical Statistics. 2018 May 4
263 citations
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-97...
Brigette B.Y. Ma, Wan-Teck Lim, Boon Cher Goh, Edwin P. Hui, Kwok Wai Lo, Adam Pettinger, Nathan R. Foster, Jonathan W. Riess, Mark Agulnik, Alex Y. Chang, Akhil Chopr...> ;Journal of Clinical Oncology. 2018 Mar 27
57 citations
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia X. Ma, César Sánchez, Feng Gao, Robert J. Crowder, Michael Naughton, Timothy J. Pluard, Allison N. Creekmore, Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Aus...> ;Clinical Cancer Research. 2016 Jun 1
52 citations
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
Cynthia X. Ma, Vera J. Suman, Matthew P. Goetz, Donald W. Northfelt, Mark E. Burkard, Foluso O. Ademuyiwa, Michael Naughton, Julie A. Margenthaler, Rebecca Aft, Richar...> ;Clinical Cancer Research. 2017 Nov 15
35 citations
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E. Wahner Hendrickson, Michael E. Menefee, Lynn C. Hartmann, Harry J. Long, Donald W. Northfelt, Joel M. Reid, Felix Boakye-Agyeman, Olumide Kayode, Karen S. Fl...> ;Clinical Cancer Research. 2017 Nov 14
48 citations
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Matthew P. Goetz, Vera J. Suman, Joel M. Reid, Don W. Northfelt, Michael A. Mahr, Andrew T. Ralya, Mary J. Kuffel, Sarah A. Buhrow, Stephanie L. Safgren, Renee M. McGo...> ;Journal of Clinical Oncology. 2017 Aug 30
18 citations
Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study
Jeremy T. Larsen, Tait D. Shanafelt, Jose F. Leis, Betsy LaPlant, T. G. Call, Adam Pettinger, Curtis A. Hanson, Charles Erlichman, Thomas M. Habermann, Craig B. Reeder...> ;American Journal of Hematology. 2017 Jun 1
37 citations
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
Tufia C. Haddad, Rui Qin, Ruth Lupu, Daniel Satele, Matthew J Eadens, Matthew P. Goetz, Charles Erlichman, Julian R. Molina> ;Cancer Chemotherapy and Pharmacology. 2017 May 5
51 citations
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Nilofer S. Azad, Anthony B. El-Khoueiry, Jun Yin, Ann L. Oberg, Patrick J. Flynn, Douglas Adkins, Anup Sharma, Daniel J. Weisenberger, Thomas M. Brown, Prakriti Medvar...> ;Oncotarget. 2017 Feb 6
75 citations
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet Lensing, Muralidhar Beeram, Julian R. Molina, Drew W. Rasco, Rebecc...> ;Clinical Cancer Research. 2016 Mar 1
2 citations
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Joleen M. Hubbard, George P. Kim, Mitesh J. Borad, Elizabeth Johnson, Rui Qin, Janet Lensing, Suneetha Puttabasavaiah, John Wright, Charles Erlichman, Axel Grothey> ;Investigational New Drugs. 2016 Feb 1
39 citations
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
Harry H. Yoon, Nathan R. Foster, Jeffrey P. Meyers, Preston D. Steen, DW Visscher, Raji Pillai, Debra M. Prow, C. M. Reynolds, Benjamin T. Marchello, Rex B. Mowat, Bas...> ;Annals of Oncology. 2016 Feb 1
9 citations
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
Ryan J. Mattison, Alcee Jumonville, Patrick J. Flynn, Alvaro Moreno-Aspitia, Charles Erlichman, Betsy LaPlant, Mark B. Juckett> ;Leukemia & Lymphoma. 2015 Jul 1
27 citations
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cance...
Brigette B.Y. Ma, Boon Cher Goh, Wan-Teck Lim, Edwin P. Hui, E. H. Tan, G. de Lima Lopes, Kwok Wai Lo, Leung Li, Herbert H. Loong, Nathan R. Foster, Charles Erlichman,...> ;Investigational New Drugs. 2015 Jun 19
88 citations
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
Timothy J. Hobday, Rui Qin, Diane Reidy-Lagunes, Malcolm J. Moore, Jonathan R. Strosberg, Andreas Kaubisch, Manisha H. Shah, Hedy L. Kindler, Heinz-Josef Lenz, Helen X...> ;Journal of Clinical Oncology. 2015 May 10
39 citations
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
Katrina S. Pedersen, George P. Kim, Nathan R. Foster, Andrea Wang-Gillam, Charles Erlichman, Robert R. McWilliams> ;Investigational New Drugs. 2015 May 8
27 citations
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.
Jennifer J. Knox, Rui Qin, Jonathan R. Strosberg, Benjamin R. Tan, Andreas Kaubisch, Anthony B. El-Khoueiry, Tanios Bekaii-Saab, Steven R. Rousey, Helen X. Chen, Charl...> ;Investigational New Drugs. 2015 Feb 1
168 citations
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
Shaji Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie S. Callander, Rafael Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart> ;Blood. 2015 Jan 15
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow
American Association for Cancer Research - AACR
Member